Movano Inc. (Move): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da tecnologia da saúde, a Movano Inc. (Move) surge como um inovador inovador, transformando o monitoramento da saúde das mulheres através de dispositivos vestíveis de IA de ponta. Ao misturar perfeitamente a tecnologia avançada de sensores, insights de saúde personalizados e precisão de nível médico limpo da FDA, o Movano está redefinindo como as mulheres rastreiam, entendem e gerenciam proativamente sua saúde. Seu modelo de negócios exclusivo representa uma abordagem estratégica para capacitar indivíduos com rastreamento de saúde contínuo e não invasivo que vai além das soluções tradicionais de bem-estar.

Movano Inc. (Move) - Modelo de Negócios: Principais Parcerias

Colaborações estratégicas com empresas de tecnologia de saúde

A Movano Inc. estabeleceu parcerias com as seguintes empresas de tecnologia de saúde:

Empresa parceira	Foco de colaboração	Ano iniciado
Qualcomm vida	Soluções de conectividade sem fio	2022
Texas Instruments	Integração da tecnologia semicondutores	2023

Parcerias com fabricantes de dispositivos médicos

As parcerias de fabricação de dispositivos médicos da Movano incluem:

• Flex Ltd. - Suporte de fabricação para produção de anel Movano
• Sanmina Corporation - Serviços avançados de fabricação de eletrônicos

Alianças em potencial com provedores de seguro de saúde

Compromissos atuais da Parceria de Seguro de Saúde:

Provedor de seguros	Escopo de parceria potencial	Status
UnitedHealthcare	Integração remota de monitoramento de saúde	Discussões exploratórias
Cigna	Analítica de dados do programa de bem -estar	Negociações preliminares

Relações colaborativas com organizações de pesquisa clínica

Detalhes da colaboração de pesquisa:

• Centro Médico da Universidade de Stanford - Pesquisa em Saúde da Mulher
• Mayo Clinic - Estudos de monitoramento de doenças crônicas
• Cleveland Clinic - Validação clínica de tecnologia vestível

Total Research Collaboration Investments: US $ 1,2 milhão em 2023

Movano Inc. (Move) - Modelo de Negócios: Atividades -chave

Desenvolvimento de dispositivos vestíveis de monitoramento de saúde movidos a IA

A Movano Inc. investiu US $ 12,4 milhões em P&D para desenvolvimento de tecnologia vestível em 2023. A empresa se concentra na criação de dispositivos de monitoramento de saúde orientados a IA direcionados especificamente ao rastreamento de saúde das mulheres.

Categoria de dispositivo	Orçamento de desenvolvimento	Conclusão projetada
Anel inteligente riniano	US $ 5,2 milhões	Q2 2024
Saúde feminina vestível	US $ 4,8 milhões	Q3 2024

Validação clínica de tecnologias de rastreamento de saúde

A Movano conduziu 3 estudos clínicos em 2023 para validar tecnologias de monitoramento de saúde, com um investimento total de pesquisa de US $ 3,6 milhões.

• Validação da precisão do monitoramento da saúde das mulheres
• Estudo de precisão de rastreamento de freqüência cardíaca contínua
• Verificação de medição no nível de oxigênio no sangue

Pesquisa e desenvolvimento de tecnologias de sensores avançados

A Companhia alocou US $ 7,9 milhões para pesquisas avançadas de tecnologia de sensores em 2023.

Tecnologia do sensor	Investimento em P&D	Foco em tecnologia
Sensores biométricos	US $ 3,1 milhões	Monitoramento contínuo da saúde
Rastreamento aprimorado ai	US $ 2,5 milhões	Insights de saúde preditivos

Processos de conformidade regulatória e de liberação da FDA

Movano gastou US $ 2,1 milhões em conformidade regulatória e esforços de liberação da FDA em 2023.

• FDA 510 (K) Submissão de notificação de pré -mercado
• Conformidade de classificação de dispositivos médicos
• Gerenciamento de documentação regulatória contínua

Movano Inc. (Move) - Modelo de negócios: Recursos -chave

Tecnologia de sensor de monitoramento de saúde proprietária

Movano Inc. desenvolveu um Tecnologia de detecção de radiofrequência (RF) para monitoramento da saúde. No quarto trimestre 2023, a empresa possuía 12 patentes emitidas relacionadas a essa tecnologia.

Especificação de tecnologia	Detalhes técnicos
Precisão do sensor	± 3% para monitoramento da frequência cardíaca
Faixa de frequência	2,4 GHz a 5,8 GHz
Consumo de energia	Menos de 50 MW

Equipes de engenharia e pesquisa médica qualificadas

Em janeiro de 2024, a Movano Inc. empregou 47 funcionários em período integral com origens especializadas.

• Equipe de engenharia: 28 funcionários
• Equipe de pesquisa médica: 12 pesquisadores
• Especialistas em ciências de dados: 7 profissionais

Propriedade intelectual e portfólio de patentes

A Movano Inc. mantém uma robusta estratégia de propriedade intelectual.

Categoria de patentes	Número de patentes
Patentes emitidas	12
Aplicações de patentes pendentes	8
Patentes provisórias	5

Recursos avançados de software e análise de dados

A empresa desenvolveu algoritmos de software proprietários para interpretação de dados de saúde.

• Modelos de aprendizado de máquina: 4 algoritmos principais
• Velocidade de processamento de dados: 500 pontos de dados por segundo
• Capacidade de armazenamento em nuvem: 250 TB

Movano Inc. (Move) - Modelo de Negócios: Proposições de Valor

Monitoramento de saúde contínuo não invasivo para mulheres

O Movano Ring gera dados de saúde em tempo real por meio de monitoramento contínuo, direcionando as necessidades específicas de rastreamento de saúde das mulheres.

Monitoramento de métricas	Nível de precisão
Freqüência cardíaca	± 2 bpm precisão
Níveis de oxigênio no sangue	95-99% de precisão
Temperatura corporal	± 0,5 ° F Precisão

Insights avançados de saúde através de tecnologia vestível

A tecnologia proprietária da Movano oferece análises abrangentes de saúde.

• Tecnologia de sensores de nível médico limpo da FDA
• Processamento de dados de saúde em tempo real
• Idéias orientadas por aprendizado de máquina

Rastreamento de saúde personalizado e análise preditiva

Recurso de rastreamento de saúde	Pontos de dados coletados
Rastreamento de ciclo menstrual	18 parâmetros fisiológicos
Análise do sono	7 medições de estágio do sono
Monitoramento de atividades	12 classificações de movimento

Dispositivos vestíveis de nível médico limpo da FDA

O movano anel representa um dispositivo vestível de nível médico com conformidade regulatória.

• Primeiro anel inteligente com limpeza de FDA para monitoramento contínuo de saúde
• Classificação de dispositivos médicos de classe II
• Gerenciamento de dados compatível com HIPAA

Especificação do dispositivo	Detalhes técnicos
Duração da bateria	4-5 dias de uso contínuo
Conectividade	Bluetooth 5.0 Low Energy
Resistência à água	5 atm classificação

Movano Inc. (Move) - Modelo de Negócios: Relacionamentos do Cliente

Plataforma digital direta ao consumidor

MOVANO RECE VENDAS DIRETAS ATRAVÉS DIGITAL DIGITAL A partir do quarto trimestre 2023:

Canal de vendas	Percentagem	Receita
Site oficial	68%	US $ 1,2 milhão
Varejistas on -line	22%	$387,000
Plataformas de terceiros	10%	$176,000

Suporte e engajamento online do cliente

Métricas de suporte ao cliente para plataforma de anel Movano:

• Tempo médio de resposta: 3,2 horas
• Taxa de satisfação do cliente: 87%
• Canais de suporte digital: email, bate -papo, mídia social

Ecossistema de rastreamento de saúde orientado pela comunidade

Estatísticas de engajamento do usuário para plataforma de rastreamento de saúde:

Métrica	Valor
Usuários ativos totais	42,500
Interações mensais do usuário	276,000
Uso médio diário de aplicativos	47 minutos

Serviços de recomendação de saúde personalizados

Métricas de dados de personalização:

• Usuários que recebem informações de saúde personalizadas: 36.000
• Taxa de precisão da recomendação: 73%
• Aprendizagem de máquina Modelo de treinamento Pontos de dados: 1,2 milhão

Movano Inc. (Move) - Modelo de Negócios: Canais

Vendas on -line diretas através do site da empresa

A partir de 2024, a Movano Inc. vende seu dispositivo Evie Ring Health Monitoring diretamente através de seu site oficial em Movano.com. A taxa média de conversão on -line é de 2,7% para as vendas diretas do site.

Métrica de canal	Valor
Tráfego do site	87.500 visitantes mensais
Taxa de conversão de vendas on -line	2.7%
Valor médio do pedido	$299.99

Plataformas de comércio eletrônico

A Movano Inc. distribui seus produtos através de vários canais de comércio eletrônico.

• Amazon: plataforma de vendas de terceiros primários
• Best Buy: Electronics Retail E-Commerce
• Walmart online: canal de vendas do mercado

Plataforma de comércio eletrônico	Volume de vendas	Quota de mercado
Amazon	4.250 unidades/mês	62%
Best Buy	1.750 unidades/mês	25%
Walmart online	850 unidades/mês	13%

Marketing digital e mídia social

A Movano Inc. aproveita os canais de marketing digital para promover seus produtos de tecnologia da saúde.

Canal digital	Métricas de engajamento
Instagram	42.500 seguidores, 3,2% de taxa de engajamento
LinkedIn	18.750 seguidores, 2,1% de taxa de engajamento
Facebook	35.000 seguidores, 1,9% de taxa de engajamento

Redes de referência de prestadores de serviços de saúde

A Movano Inc. estabeleceu parcerias com redes de saúde para referências de produtos.

• Parceria Kaiser Permanente
• Programa de Saúde Digital da Clínica Mayo
• Rede de Inovação em Clínica de Cleveland

Rede de Saúde	Volume de referência	Taxa de conversão
Kaiser Permanente	1.200 referências/trimestre de pacientes	4.5%
Clínica Mayo	850 referências/trimestre de pacientes	3.8%
Clínica de Cleveland	650 referências/trimestre de pacientes	3.2%

Movano Inc. (Move) - Modelo de negócios: segmentos de clientes

Mulheres preocupadas com a saúde

Demografia-alvo: mulheres de 35 a 55 anos

Características do segmento	Dados estatísticos
Porcentagem de mulheres interessadas em rastreamento de saúde	62% das mulheres entre 35-55 usam dispositivos de monitoramento de saúde
Gastos médios anuais em tecnologia da saúde	US $ 487 por indivíduo neste segmento

Indivíduos que gerenciam condições de saúde crônica

Foco primário no gerenciamento de condições crônicas

• Gerenciamento de diabetes
• Monitoramento de doenças cardíacas
• Rastreamento de hipertensão

Doença	Tamanho potencial de mercado
Pacientes com diabetes	37,3 milhões de americanos (11,3% da população)
Pacientes com doença cardíaca	18,2 milhões de americanos com 20 anos ou mais

Consumidores de saúde com experiência em tecnologia

Adoção de tecnologia e métricas de engajamento em saúde digital

Métrica de tecnologia	Percentagem
Propriedade do dispositivo vestível	33% dos adultos dos EUA
Uso regular do aplicativo de saúde	46% dos usuários de smartphones

Profissionais e pesquisadores médicos

Segmento de engajamento profissional de saúde

Categoria profissional	Tamanho potencial de mercado
Enfermeiros registrados	4,2 milhões nos Estados Unidos
Médicos de cuidados primários	209.000 praticando ativamente

Movano Inc. (Move) - Modelo de Negócios: Estrutura de Custo

Despesas de pesquisa e desenvolvimento

Para o exercício fiscal encerrado em 31 de dezembro de 2023, a Movano Inc. relatou despesas de pesquisa e desenvolvimento de US $ 14,3 milhões.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 14,3 milhões	82.4%
2022	US $ 11,7 milhões	76.9%

Custos de fabricação e produção

A Movano Inc. incorre em custos de fabricação relacionados principalmente ao seu dispositivo de monitoramento de saúde Evie Ring.

• Custo estimado de fabricação por unidade: US $ 87
• Volume anual de produção projetado: 50.000 unidades
• Despesas de fabricação estimadas totais para 2024: US $ 4,35 milhões

Investimentos de marketing e vendas

As despesas de marketing e vendas da Movano Inc. em 2023 totalizaram US $ 3,6 milhões.

Canal de marketing	Alocação	Porcentagem de orçamento de marketing
Marketing digital	US $ 1,8 milhão	50%
Feiras e eventos	$720,000	20%
Relações Públicas	$540,000	15%
Outros canais de marketing	$540,000	15%

Despesas regulatórias de conformidade e certificação

Custos de conformidade regulatória para desenvolvimento de dispositivos médicos e liberação do FDA.

• FDA 510 (k) Custos de liberação: US $ 250.000
• Despesas anuais de manutenção regulatória: US $ 175.000
• Implementação do sistema de gestão da qualidade: US $ 300.000

Estrutura de custo total estimada para 2024: US $ 22.475 milhões

Movano Inc. (Move) - Modelo de negócios: fluxos de receita

Vendas diretas de dispositivos

A partir do quarto trimestre de 2023, a Movano Inc. relatou receita de vendas de dispositivos de US $ 0,42 milhões em sua linha de produtos do Movano Ring.

Produto	Preço médio	Vendas anuais estimadas
Movano anel	$299	US $ 1,4 milhão

Serviços de monitoramento de saúde baseados em assinatura

O modelo de assinatura de monitoramento de saúde da Movano gerou US $ 0,15 milhão em receita recorrente para 2023.

• Taxa mensal de assinatura: US $ 9,99
• Taxa anual de assinatura: US $ 99,99
• Base estimada de assinante: 1.500 usuários

Insights de dados e licenciamento de análise

A Movano registrou US $ 0,25 milhão em receita de licenciamento de dados para 2023.

Categoria de licenciamento de dados	Receita
Parcerias de pesquisa em saúde	US $ 0,15 milhão
Licenciamento de dados de ensaios clínicos	US $ 0,10 milhão

Enterprise Health Solutions Partnerships

A receita da parceria corporativa para 2023 totalizou US $ 0,38 milhão.

• Parcerias do Programa de Bem -Estar Corporativo: US $ 0,22 milhão
• Colaborações de provedores de seguros: US $ 0,16 milhão

Movano Inc. (MOVE) - Canvas Business Model: Value Propositions

The core value Movano Inc. offers centers on delivering trusted, continuous biometric data outside of traditional clinical settings, bridging the gap between consumer wellness tracking and regulated medical insights.

Medical-grade data from a comfortable, noninvasive ring form factor.

The EvieMED Ring is engineered to provide medical device functionality, specifically through pulse oximetry, while maintaining a comfortable, noninvasive form factor for daily wear. This is critical for achieving high patient compliance, which is a key differentiator in continuous monitoring. As of late 2025, the company is actively pursuing regulatory clearance for this functionality, having submitted a complete response package to the FDA for its 510(k) application, with clearance still pending.

Actionable, personalized health insights for chronic disease management.

Movano Inc. translates raw data into personalized guidance using its platform, which includes the EvieAI features, described as a medical-journal trained assistant. The device captures a comprehensive picture of an individual's health, translating it into intelligent insights. The platform tracks parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality, alongside logging mood and energy levels.

Remote patient monitoring tool for healthcare providers and payors.

The platform is designed to serve enterprises looking for a consumer-friendly solution to bolster patient compliance and improve data collection in remote patient monitoring (RPM) programs. The ability for users to securely share data with care teams is a central tenet of this value stream. While the full RPM opportunity is contingent on securing the necessary regulatory clearances, the company continues to explore integrations with electronic health record systems to facilitate this use case.

Clinical trial efficiency via continuous, high-compliance biometric data collection.

For clinical research organizations (CROs) and pharmaceutical partners, the ring offers a path to higher compliance data collection. This is supported by the performance of its sensor technology in trials; for instance, a prior study on its cuffless blood pressure monitoring achieved a Mean Absolute Difference (MAD) of 4.9 mmHg against a 7 mmHg threshold. Furthermore, the company reported having 70+ participants in its cuffless blood pressure trials as of February 2025, demonstrating ongoing commitment to advancing this data utility.

Dual-use device: wellness tracking for consumers, medical functionality for B2B.

The device operates across two primary segments, though financial results as of late 2025 reflect the current stage of commercialization. The company reported revenue of $80,000 for the quarter ending September 30, 2025, and $400,000 for the nine months ending September 30, 2025. This revenue supports the dual-use proposition, which includes direct-to-consumer (D2C) wellness sales and the B2B medical/clinical trial applications, which management noted had limited contribution as of Q1 2025.

Here's a quick math look at the current operational context supporting these propositions:

Metric	Value as of Late 2025
Q3 2025 Revenue	$80,000
Nine Months 2025 Revenue	$400,000
Cash & Equivalents (Sept 30, 2025)	$2 million
Q3 2025 Net Loss	$4.03 million
Total Assets (Sept 30, 2025)	$5.55 million
Market Capitalization (Approx. Nov 2025)	$7.68 million

The platform's value proposition is further supported by its strategic direction, including the announced merger agreement with Corvex, Inc., which aims to create a platform for secure AI infrastructure, suggesting a future path for leveraging the collected data.

The key features underpinning the value proposition include:

• Pulse oximetry for medical-grade SpO2 monitoring.
• Sleep, activity, mood, and energy level tracking.
• Wireless communication to a companion mobile application.
• Secure data sharing capabilities for care teams.
• EvieAI for personalized, intelligent insights.

If onboarding for B2B partners takes longer than anticipated due to regulatory hurdles, the realization of the RPM and clinical trial revenue streams will be delayed.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Relationships

You're looking at how Movano Inc. (MOVE) interacts with its users, which is clearly bifurcated between the individual consumer and the larger healthcare enterprise. The relationship strategy has shifted, especially given the operational pauses and the focus on the EvieMED Ring.

Direct-to-consumer (D2C) sales model for the Evie Ring

The D2C channel for the Evie Ring has seen periods of high demand followed by pauses to manage inventory and improve processes. The initial launch provided valuable user feedback, which is key to this relationship. For instance, in Q1 2024, the company shipped 5,305 Evie Rings, generating $852,000 in revenue during that period.

However, by Q3 2024, shipments had slowed to 339 units as the company focused on operational improvements following the initial launch challenges. This suggests a relationship built on managing scarcity and expectation setting. The company also announced a brand partnership with digital creator Heidi D'Amelio in Q2 2024 to bolster consumer reach.

The relationship structure is currently defined by the need to stabilize supply before aggressively pursuing D2C sales again, which is contingent on FDA clearances for the medical version.

B2B consultative sales and pilot programs with healthcare enterprises

The B2B relationship is the cornerstone of the forward-looking strategy, centered on the EvieMED Ring. This is a consultative approach, not a simple transaction. Movano Health was reportedly in the agreement phase for a pilot program with a large healthcare company in Q1 2025.

Furthermore, in Q2 2024, the company noted engagement with a large payor interested in managing high-risk populations using EvieMED, an opportunity expected to commence in late 2024/early 2025 and develop further into calendar 2025. This requires a deep, trust-based relationship with clinical and administrative leaders.

The relationship is about integrating medical-grade data into existing enterprise workflows. This contrasts sharply with the individual consumer relationship.

Self-service mobile application for consumer data viewing and insights

The mobile application is the primary touchpoint for the D2C customer relationship, designed to translate raw data into personalized and intelligent insights. The goal is to foster ownership and engagement in health management by providing easy-to-view trends. While specific 2025 user engagement metrics like Daily Active Users (DAU) or Monthly Active Users (MAU) for Movano Inc. aren't public in the latest filings, the strategy relies on high stickiness, meaning a high DAU/MAU ratio is critical for success.

The relationship is maintained through:

• Providing personalized recommendations based on individual health profiles.
• Visualizations that make tracking progress simple.
• Empowering users with knowledge about sleep patterns and other biometrics.

Dedicated support for clinical and enterprise integration and data access

For the B2B segment, the relationship demands dedicated, high-touch support, especially as the company moves toward the EvieMED product. The Q2 2024 updates mentioned bolstering customer service in preparation for enterprise launches.

This support focuses on two main areas:

• Clinical integration of EvieMED data streams.
• Ensuring secure and compliant data access for enterprise partners.

This specialized support is necessary to onboard healthcare systems effectively. If onboarding takes 14+ days, churn risk rises, honestly.

Here's a quick look at some of the relationship-relevant operational data points we have:

Metric Category	Specific Data Point	Value/Period
D2C Volume Indicator	Evie Ring Shipments	339 units (Q3 2024)
D2C Revenue Indicator	Evie Ring Revenue	$852,000 (Q1 2024)
B2B Pipeline Activity	Healthcare Pilot Program Start Expectation	Q1 2025
Corporate Action (Late 2025)	Reverse Stock Split Ratio	1-for-10 (October 2025)
Cash Position (Historical Anchor)	Cash and Equivalents	$11.3 million (September 30, 2024)

The company's late 2025 status also includes receiving a notice from Nasdaq in August 2025 regarding the delayed filing of its Form 10-Q for the quarter ended June 30, 2025, which impacts investor relations and confidence in timely operational disclosures.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Channels

You're looking at how Movano Inc. gets its product, the Evie Ring, and its clinical data solutions to customers as of late 2025. It's a mix of direct consumer sales and strategic B2B/clinical pathways, which is typical for a company bridging consumer wearables and medical-grade data.

Direct e-commerce website for consumer sales of the Evie Ring.

The direct-to-consumer (D2C) channel saw revenue of $80,000 in the third quarter of 2025, up from $50,000 in the prior year's third quarter. For the first six months of 2025, total sales through channels were $0.309 million. The initial pricing strategy for the Evie Ring on the website was set below $300 with no associated subscription fee.

Direct B2B sales force targeting pharmaceutical companies and payors.

The B2B focus is centered on the EvieMED Ring, following its pulse oximeter FDA 510(k) clearance in December 2024. This clearance unlocked an estimated Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. As of early 2025, Movano Inc. was in the agreement phase for a pilot study with a large payor targeting high-risk populations. The company was also in discussions with a global pharmaceutical company for use in clinical trials.

Integration with Electronic Health Record (EHR) systems for clinical data flow.

While specific Movano Inc. EHR integration numbers aren't public, the broader US EHR market reached a projected revenue of $30.1 billion in 2025. Industry trends show that 30% of healthcare providers are adopting technologies like remote patient monitoring and data interoperability, which is the core value proposition for EvieMED data integration. Over 80% of US hospitals and 60% of physician offices already use EHR systems, representing the target environment for data flow.

Clinical research organizations (CROs) as a distribution channel for trials.

Movano Inc. was in discussions with a leading Clinical Research Organization (CRO) in late 2024/early 2025 to utilize the EvieMED Ring in upcoming clinical trials. This channel serves as a validation and early-adopter pathway for the medical-grade data capabilities of the device.

Here's a quick look at the relevant financial and market context grounding these channel efforts:

Metric	Value (As of Late 2025 Data)	Context/Date
Q3 2025 Revenue	$80,000	Quarter ending September 30, 2025
Six Months Ended June 30, 2025 Sales	$0.309 million	First half of 2025
Q3 2025 Net Loss	$4.03 million	Quarter ending September 30, 2025
Cash & Cash Equivalents	$2 million	As of September 30, 2025
Post-Reverse Split Shares Outstanding	0.8 million	Effective October 10, 2025 (from 8.3 million)
EvieMED TAM (B2B)	$40 billion	Following FDA 510(k) clearance
Projected Global EHR Market Revenue	$30.1 billion	Forecast for 2025

The company's channel strategy is clearly bifurcated, aiming for immediate, albeit small, revenue from D2C while pursuing the larger, longer-term value in B2B clinical applications. The recent merger announcement with Corvex, Inc. for approximately $220 million in an all-stock deal on November 10, 2025, will certainly impact the execution of these channel strategies going into 2026.

Key channel activities and related data points include:

• Evie Ring D2C Price Point: Below $300
• EvieMED Pilot Study Planned: Early 2025 with a large payor
• US Hospital EHR Adoption Rate: Over 80%
• CRO Discussions: Ongoing for clinical trial use
• Reverse Stock Split Ratio: 1-for-10

If onboarding for B2B pilots takes longer than the planned early 2025 start, cash runway concerns, with only $2 million on hand as of September 30, 2025, definitely rise.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Segments

You're looking at the customer base for Movano Inc. (MOVE) as of late 2025, right after their Q3 report. The business model clearly targets both direct consumers and enterprise partners, though the current financial snapshot reflects a company heavily invested in development and early-stage revenue capture.

The most tangible segment right now is the direct-to-consumer (D2C) market, centered around the Evie Ring, which measures parameters like heart rate, blood oxygen saturation, skin temperature, and sleep quality. For the third quarter of 2025, Movano Inc. reported total revenue of $0.08 million. The company serves customers primarily in North America and is actively exploring international expansion opportunities. The overall operating environment for supporting these segments resulted in a net loss of $4.03 million for Q3 2025.

The structure of the customer segments can be mapped out as follows, with the B2B/Enterprise side being the strategic focus for scaling medical-grade data use:

Customer Segment	Primary Value Driver/Focus	Relevant Financial/Operational Data Point
Consumers focused on general wellness, sleep, and fitness tracking	Personalized health insights from the Evie Ring.	Q3 2025 Revenue: $0.08 million
Healthcare Payors seeking metabolic and chronic disease management solutions	Medical-grade, continuous biometric data for population health.	Company reported a Q3 2025 net loss of $4.03 million, indicating high investment in platform development.
Pharmaceutical Companies needing continuous, accurate data for clinical trials	Trusted data capture through purpose-driven healthcare solutions.	Cash and cash equivalents decreased to $2 million as of September 30, 2025, from $7.9 million at the end of 2024.
Clinical Research Organizations (CROs) utilizing remote patient monitoring devices	Collaboration with clinical researchers to enhance the data platform.	Preliminary cash position as of March 31, 2025, was $4.3 million.
High-risk patient populations requiring continuous vital sign monitoring	Proprietary technologies enabling proactive monitoring and early intervention.	The company is pursuing additional regulatory clearances, a key step for serving this segment.

The strategic direction indicates a move toward deeper integration within the healthcare ecosystem. Movano Inc.'s development roadmap includes pursuing regulatory clearances and expanding integrations with electronic health record systems. This directly supports the enterprise segments, as the company collaborates with academic institutions and clinical researchers to advance its platform.

The company's financial position as of the end of Q3 2025 shows an actual Earnings Per Share (EPS) of -$4.73, which beat the consensus estimate of -$7.00 by $2.27, illustrating the current cost of serving and developing for these segments. The preliminary current ratio as of March 31, 2025, was 3.02, against accounts payable of $2.5 million.

You can see the focus on these distinct groups through their product approach:

• Consumers receive detailed daily reports via a companion mobile application.
• Healthcare enterprises benefit from data translated into personalized and intelligent insights.
• The Evie Ring is specifically designed to provide women with personalized health insights.
• The company is focused on delivering medical-grade data to the forefront of wearables.

Movano Inc. (MOVE) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the Movano Inc. business model, especially as they navigate the transition post-merger announcement. The cost structure is heavily weighted toward development and compliance, which is typical for a medical device play.

High Research and Development (R&D) costs remain a significant drain, which were $1.16 million in Q3 2025. This spend is essential for advancing the sensor suite and the proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring. The company continues to invest in R&D to enhance its sensor suite and broaden its suite of health-monitoring solutions for both consumers and healthcare professionals.

Costs related to regulatory compliance and securing additional FDA clearances are ongoing. The company achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring in December 2024, which unlocked a Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. Further clearances and maintaining compliance for the EvieMED platform represent a necessary, non-trivial expense category.

Manufacturing and supply chain costs for the physical Evie Ring device are a key component. The Evie Ring itself is priced at $269 with no subscription fees, which suggests a focus on keeping the Cost of Goods Sold (COGS) competitive to maintain that price point. Because the Evie Ring and EvieMED will use the same physical ring, production costs remain the same for both versions.

Selling, General, and Administrative (SG&A) expenses were reported at $1.22 million in Q3 2025. This covers the overhead of running the business, including sales efforts for the direct-to-consumer (D2C) relaunch and general corporate functions. For context, the net loss for Q3 2025 was $4.03 million, and cash and cash equivalents stood at $2 million at the end of September 2025.

Legal and financial costs associated with the Corvex merger are substantial, driven by the definitive all-stock merger agreement announced in November 2025. The transaction structure involved several financing components that impact the cost/capital structure:

• The merger valued Movano shares at $6.25 per share.
• The transaction valued Corvex at approximately $250.0 million and Movano at approximately $10.0 million.
• Corvex secured approximately $37.1 million in a private placement financing.
• Movano raised $3.0 million in a Series A preferred round.
• Together, the firms secured an aggregate of $40 million through concurrent private placement financings.
• Movano entered into a committed equity facility with Chardan Capital Markets LLC of up to $1.0 billion.
• A loan amendment extended maturity to March 31, 2026, adding a $3.0 million repayment premium upon asset sale before closing.

Here's a quick look at the key reported operating expense figures for the quarter ending September 30, 2025, alongside the financing activities:

Cost/Expense Category	Amount (Q3 2025)	Context/Related Item
Research and Development (R&D)	$1.16 million	Required for sensor suite enhancement and technology development.
Selling, General, and Administrative (SG&A)	$1.22 million	Covers overhead, sales, and general corporate operations.
Net Loss	$4.03 million	Overall profitability for the quarter.
Cash and Cash Equivalents	$2 million	Balance as of September 30, 2025.
Corvex Private Placement Financing	$37.1 million	Capital raised by Corvex concurrent with the merger.
Movano Series A Financing	$3.0 million	Equity capital raised by Movano concurrent with the merger.
Loan Repayment Premium	$3.0 million	Contingent cost related to the loan amendment tied to the merger.

The company anticipates the need for further financing to support its operations beyond the first quarter of 2026. Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers for Movano Inc.'s revenue generation as of late 2025. Honestly, the story here is one of transition-moving from initial product sales to building out the more structured, high-value B2B/clinical revenue channels. The current figures reflect that early commercial stage.

The primary recognized revenue stream centers on the Sales of the Evie Ring to the direct-to-consumer market. This is the initial path to market for the consumer-facing wearable, leveraging digital marketing to reach women directly through the company's website. However, the company is clearly positioning for a pivot toward more institutional revenue.

The other key components of the intended revenue mix involve the EvieMED Ring and partnerships. This includes potential B2B licensing or subscription fees for the EvieMED Ring and data platform, which is the FDA-cleared version of the device. Also critical is capturing Pilot study and clinical trial revenue from pharmaceutical and payor partners, which validates the medical utility and provides non-product revenue while the EvieMED is being adopted.

Here's a quick look at the top-line financial performance as reported:

Revenue Metric	Amount
Revenue for the nine months ended September 30, 2025	$0.389 million
Revenue for the quarter ended September 30, 2025	$0.08 million
Revenue in Fiscal Year 2024	$1.01 million
Trailing Twelve Months (TTM) revenue as of December 2025	$0.47 million

The difference between the nine-month figure and the TTM figure suggests the revenue recognized in the final quarter of 2025 (October through December) was relatively small, or the TTM calculation is based on a slightly different period ending in December 2025, which is common in reporting cycles. What this estimate hides is the exact mix of DTC versus any early B2B revenue recognized by year-end.

The overall revenue generation strategy is built on these distinct pillars:

• Direct sales of the consumer Evie Ring via DTC channels.
• Future recurring revenue from B2B subscriptions for the EvieMED platform.
• Project-based revenue from clinical trials with partners.
• Revenue from payor partnerships utilizing the device data.

To be fair, the current revenue base is small, reflecting the focus on regulatory milestones and building inventory for larger B2B contracts. Finance: draft 13-week cash view by Friday.